Compare Johnson & Johnson (JNJ) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Meta Platforms Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Meta Platforms Inc trades at $717.92 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 3× Johnson & Johnson's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Meta Platforms Inc for 127 Days on average.
| JNJ | META | |
|---|---|---|
Market Cap | $618.09B | $1.84T |
Volume | 6,050,983 | 15,887,049 |
Sector | Health | Media |
52-Week High | $278.43 | $777.59 |
52-Week Low | $186.00 | $525.72 |
Typical Hold Time | 129 Days | 127 Days |
Enterprise Value | $646.37B | $1.86T |
Dividend Yield | 2.09% | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
META trades at $718.67, down 0.37% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $201B in 2025 and maintains robust profitability with 29.84% net margins. Recent AI developments, including the Muse Spark launch, and a $21B deal with CoreWeave highlight strategic positioning. Analyst consensus is strongly bullish with an 80% buy rating and $781 price target, though legal challenges and high capital expenditures present headwinds.
META's outlook remains positive driven by AI innovation and solid fundamentals, but investors face risks from regulatory lawsuits and volatile tech sentiment. The stock offers upside to consensus targets if execution continues, yet high valuation multiples and market rotation pressures warrant caution. Balancing growth prospects with legal and competitive risks is key for medium-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
